Assenagon Asset Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $171M | Buy |
341,813
+155,377
| +83% | +$74.6M | 0.21% | 83 |
|
|
2026
Q1 | $91.6M | Buy |
186,436
+175,696
| +1,636% | +$95.4M | 0.14% | 128 |
|
|
2025
Q4 | $6.22M | Sell |
10,740
-604,595
| -98% | -$342M | 0.01% | 605 |
|
|
2025
Q3 | $298M | Buy |
615,335
+573,743
| +1,379% | +$267M | 0.41% | 43 |
|
|
2025
Q2 | $16.9M | Sell |
41,592
-112,137
| -73% | -$46.9M | 0.03% | 380 |
|
|
2025
Q1 | $76.5M | Buy |
153,729
+133,719
| +668% | +$72.4M | 0.13% | 137 |
|
|
2024
Q4 | $10.4M | Sell |
20,010
-31,033
| -61% | -$17.1M | 0.02% | 509 |
|
|
2024
Q3 | $31.6M | Sell |
51,043
-420,932
| -89% | -$249M | 0.06% | 245 |
|
|
2024
Q2 | $261M | Buy |
471,975
+422,341
| +851% | +$242M | 0.58% | 29 |
|
|
2024
Q1 | $28.8M | Sell |
49,634
-55,075
| -53% | -$30.9M | 0.07% | 223 |
|
|
2023
Q4 | $55.6M | Buy |
104,709
+13,043
| +14% | +$6.31M | 0.15% | 120 |
|
|
2023
Q3 | $46.4M | Buy |
91,666
+53,563
| +141% | +$28.5M | 0.14% | 126 |
|
|
2023
Q2 | $19.9M | Sell |
38,103
-282,365
| -88% | -$152M | 0.07% | 232 |
|
|
2023
Q1 | $185M | Buy |
320,468
+104,912
| +49% | +$59.1M | 0.66% | 29 |
|
|
2022
Q4 | $119M | Buy |
215,556
+73,877
| +52% | +$39.1M | 0.43% | 42 |
|
|
2022
Q3 | $71.9M | Buy |
141,679
+91,282
| +181% | +$51.1M | 0.28% | 80 |
|
|
2022
Q2 | $27.4M | Sell |
50,397
-187,183
| -79% | -$103M | 0.1% | 184 |
|
|
2022
Q1 | $140M | Buy |
237,580
+170,109
| +252% | +$97.7M | 0.39% | 47 |
|
|
2021
Q4 | $45M | Sell |
67,471
-90,609
| -57% | -$56.6M | 0.13% | 110 |
|
|
2021
Q3 | $90.3M | Buy |
158,080
+84,077
| +114% | +$46.1M | 0.29% | 62 |
|
|
2021
Q2 | $37.3M | Sell |
74,003
-36,705
| -33% | -$17.3M | 0.13% | 144 |
|
|
2021
Q1 | $50.5M | Sell |
110,708
-10,470
| -9% | -$5M | 0.21% | 86 |
|
|
2020
Q4 | $56.4M | Buy |
121,178
+119,006
| +5,479% | +$55.8M | 0.25% | 82 |
|
|
2020
Q3 | $959K | Sell |
2,172
-46,930
| -96% | -$19.4M | 0.01% | 808 |
|
|
2020
Q2 | $17.8M | Sell |
49,102
-137,536
| -74% | -$46.1M | 0.11% | 116 |
|
|
2020
Q1 | $52.9M | Buy |
186,638
+180,464
| +2,923% | +$56.9M | 0.42% | 52 |
|
|
2019
Q4 | $2.01M | Sell |
6,174
-148,826
| -96% | -$45.1M | 0.01% | 443 |
|
|
2019
Q3 | $45.1M | Buy |
155,000
+49,831
| +47% | +$14.3M | 0.3% | 71 |
|
|
2019
Q2 | $30.9M | Buy |
105,169
+27,276
| +35% | +$7.51M | 0.23% | 79 |
|
|
2019
Q1 | $21.3M | Buy |
77,893
+21,229
| +37% | +$5.28M | 0.2% | 102 |
|
|
2018
Q4 | $12.7M | Buy |
56,664
+38,692
| +215% | +$9.08M | 0.14% | 119 |
|
|
2018
Q3 | $4.39M | Sell |
17,972
-39,476
| -69% | -$9.08M | 0.04% | 328 |
|
|
2018
Q2 | $11.9M | Sell |
57,448
-14,540
| -20% | -$3.09M | 0.14% | 163 |
|
|
2018
Q1 | $14.9M | Buy |
+71,988
| New | +$15.1M | 0.19% | 126 |
|
|
2017
Q4 | – | Sell |
-40,243
| Closed | -$7.61M | – | 763 |
|
|
2017
Q3 | $7.61M | Buy |
+40,243
| New | +$7.29M | 0.07% | 210 |
|
Other funds holding TMO
Assenagon Asset Management's TMO Position: Q2 2026 in Review
Assenagon Asset Management increased its Thermo Fisher Scientific (TMO) stake by 83% in Q2 2026, buying an estimated $74.6M and bringing the position to 341,813 shares worth $171M. The position accounts for 0.21% of the portfolio, ranked #83.
Assenagon Asset Management first reported a position in TMO in Q3 2017 and has held it in 35 quarters since. The position peaked at $298M in Q3 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Assenagon Asset Management held 341,813 shares of Thermo Fisher Scientific worth $171M as of Q2 2026.
- Assenagon Asset Management bought 155,377 Thermo Fisher Scientific shares in Q2 2026, an estimated $74.6M.
- Thermo Fisher Scientific made up 0.21% of Assenagon Asset Management's portfolio in Q2 2026, its #83 holding.
- Assenagon Asset Management first reported a position in Thermo Fisher Scientific in Q3 2017 and has held it in 35 quarters since.
- Assenagon Asset Management's Thermo Fisher Scientific position peaked at $298M in Q3 2025.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.